Category: approve

AB FinWright, analysis, analytics, approval, approve, business, Business Analysis, cannabis, Cannabis Regulatory Enforcement Assistance and Marketplace Modernization Act, compliance, consumer, CQC, CQCExpo, CREAMM Act, cultivation, dispensary, extraction, Federal, government, growing, industry, law, legal, legalization, legalize, legislation, license, licenses, licensing, marijuana, market, medical, medicine, new jersey, NJ, Operations, product, Quality, recreational, regulation, regulations, regulatory, retail, safety, sales, state, taxes, thc, the garden state

New Jersey’s Careful Approach to Cannabis: Part One

New Jersey’s Careful Approach to Cannabis: Part One

This is Part One where we examine the state of the market, licensing, approvals and sales. Part Two will delve into all things […]

adult, analysis, analytics, applicant, application, apply, approval, approve, approved, Ascend, Ayr, business, Business Analysis, cannabis, Cannabis Regulatory Commission, compliance, conditional, CQC, CQCExpo, CRC, curaleaf, dispensaries, Dispensaries & Retail, dispensary, executive director, government, growing, industry, Jeff Brown, lab, laboratories, laboratory, labs, law, legal, legalization, legalize, legislation, license, licensing, location, marijuana, market, medical, medicine, meeting, municipality, new jersey, NJ, NJCRC, notes, product, public, Quality, rec, recreational, regulation, regulations, regulators, regulatory, retail, safety, sales, state, TerrAscend, test, testified, testify, thc, use, wellness

One Month In: New Jersey Market Starts Growing

One Month In: New Jersey Market Starts Growing

Just over a month ago, a handful of dispensaries in New Jersey began selling cannabis to adults over the age of 21. […]

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]